SynCardia Systems, LLC

SynCardia Systems, LLC, a subsidiary of Picard Medical, is the developer of the world's first and only FDA-approved Total Artificial Heart (STAH). The STAH is indicated as a bridge to transplant for patients with end-stage biventricular heart failure who are at imminent risk of death.

Since its first clinical use, the STAH has been implanted in more than 2,100 patients worldwide and has provided over 250,000 days of life-sustaining circulatory support. By replacing both failing ventricles and all four heart valves, the SynCardia TAH restores blood flow and offers critically ill patients an opportunity to survive until a donor heart becomes available.

SynCardia and Picard Medical are also advancing the future of mechanical circulatory support through the development of the Emperor Total Artificial Heart, a next-generation fully implantable artificial heart platform.

Headquartered in Tucson, Arizona.